<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Curanex Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock</link>
<description>Latest news and press releases for Curanex Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/curanex-pharmaceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo695e56ca905484111c2fedc8.webp</url>
<title>Curanex Pharmaceuticals Inc</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock</link>
</image>
<item>
<title>Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-expands-its-drug-development-pipeline-to-include-cancer-cachexia-representing-a-multi-billion-dollar-market-opportunity-and-important-step-in-the-companys-evolution-into-a-broader-therapeutics-development-company-84</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-expands-its-drug-development-pipeline-to-include-cancer-cachexia-representing-a-multi-billion-dollar-market-opportunity-and-important-step-in-the-companys-evolution-into-a-broader-therapeutics-development-company-84</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex</description>
</item>
<item>
<title>Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-provides-business-update-in-connection-with-2025-annual-report-as-phyto-n-advances-toward-planned-ind-submission</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-provides-business-update-in-connection-with-2025-annual-report-as-phyto-n-advances-toward-planned-ind-submission</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York,</description>
</item>
<item>
<title>Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-achieves-key-preclinical-milestone-with-favorable-toxicology-profile-at-maximum-dose-advancing-toward-ind-submission</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-achieves-key-preclinical-milestone-with-favorable-toxicology-profile-at-maximum-dose-advancing-toward-ind-submission</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP</description>
</item>
<item>
<title>Curanex Expands Scientific Advisory Board With Two Distinguished Researchers</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-expands-scientific-advisory-board-with-two-distinguished-researchers-1</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-expands-scientific-advisory-board-with-two-distinguished-researchers-1</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York,</description>
</item>
<item>
<title>Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-appoints-two-veteran-industry-leaders-to-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-appoints-two-veteran-industry-leaders-to-scientific-advisory-board</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Curanex Forms World Class Scientific Advisory Board</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-forms-world-class-scientific-advisory-board-5</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-forms-world-class-scientific-advisory-board-5</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex</description>
</item>
<item>
<title>Curanex Provides Operational Update on Key Regulatory Milestones</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-provides-operational-update-on-key-regulatory-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-provides-operational-update-on-key-regulatory-milestones</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex</description>
</item>
<item>
<title>Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-engages-strategic-110000240</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-engages-strategic-110000240</guid>
<pubDate>Wed, 22 Oct 2025 11:00:00 GMT</pubDate>
<description>Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’s</description>
</item>
<item>
<title>Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-exercise-184600465</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-exercise-184600465</guid>
<pubDate>Fri, 12 Sep 2025 18:46:00 GMT</pubDate>
<description>Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari Securities LLC, which acted as the lead underwriter for the Company’s underwritten initial public offering (the “Offering” or the “IPO”), has exercised in full the over-allotment option the Company granted to the und</description>
</item>
<item>
<title>Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-closing-210000151</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-closing-210000151</guid>
<pubDate>Wed, 27 Aug 2025 21:00:00 GMT</pubDate>
<description>Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the closing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering</description>
</item>
<item>
<title>Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering</title>
<link>https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-pricing-113000066</link>
<guid isPermaLink="true">https://6ix.com/company/curanex-pharmaceuticals-inc-common-stock/news/curanex-pharmaceuticals-inc-announces-pricing-113000066</guid>
<pubDate>Tue, 26 Aug 2025 11:30:00 GMT</pubDate>
<description>Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering</description>
</item>
</channel>
</rss>